Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Microbot Medical Inc.MBOT · Entity 6767 | Chief Medical Officer | August 01, 2023 | August 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Microbot Medical Inc.
Report date August 01, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2033-08-01 | Direct | 17,500 |
Reported balance
After 2023-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-01 · Grant · Acquired 17,500 · Balance 17,500 F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2023 Filed Aug 3, 2023 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-23-026629 · ownership.xml · derivative · entry 1 Morag Eyal · CIK 0001805787 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock, par value $0.01 per share · 17,500 shares Expires 2033-08-01 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 13:27 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001493152-23-001824 · ownership.xml · derivative · entry 1 Morag Eyal · CIK 0001805787 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock, par value $0.01 per share · 35,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 17, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001493152-22-002553 · ownership.xml · derivative · entry 1 Morag Eyal · CIK 0001805787 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 26, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 21:05 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.16 | $0.00 |
DisclosureSEC source: 0001493152-20-013462 · ownership.xml · derivative · entry 1 Morag Eyal · CIK 0001805787 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2030-07-14 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan (the "Plan"): (a) on December 15, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan and with respect to certain business transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.